Liver transplantation: New treatment for mucopolysaccharidosis type VI in rats

Sumika Toyama, Ohsuke Migita, Masayuki Fujino, Tetsuo Kunieda, Motomichi Kosuga, Yasuyuki Fukuhara, Yukitoshi Nagahara, Xiao Kang Li, Torayuki Okuyama

Research output: Contribution to journalArticle

Abstract

Background: Mucopolysaccharidosis (MPS) VI is a rare, autosomal recessive congenital metabolic disorder caused by deficient activity of the lysosomal metabolic enzyme, N-acetylgalactosamine 4-sulfatase. Enzyme replacement therapy (ERT) is the current treatment for MPS VI, although it involves limited compliance to the therapy and high cost. The aim of this study was to develop a new method of treatment by conducting an orthotopic liver transplantation (LTx) using an animal model of human MPS VI, and to evaluate and examine its effectiveness for treating MPS VI. Methods: LTx was carried out from normal unaffected to affected MPS VI rats (MPR), which were then killed after LTx, and tissues from the heart, spleen, and knee joint, as well as serum, collected for biological and morphologic evaluation. Results: Liver-transplanted (LTx) MPR had the same level of N-acetylgalactosamine 4-sulfatase activity in the liver and lungs as normal unaffected MPR, and the urinary secretion of mucopolysaccharides/glycosaminoglycan (GAG) in LTx MPR was significantly decreased. Furthermore, on histopathology, the spleens of LTx MPR showed elimination of vacuole cells. In the knee joints, growth plates became thinner, and on radiography the facial and cranial bones of LTx MPR were morphologically normal. Conclusions: LTx from normal to affected MPR was effective for symptoms of MPS and accumulation of GAG, suggesting that LTx could be a promising alternative approach for MPS VI.

Original languageEnglish
Pages (from-to)180-189
Number of pages10
JournalPediatrics International
Volume61
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Mucopolysaccharidosis VI
Liver Transplantation
N-Acetylgalactosamine-4-Sulfatase
Glycosaminoglycans
Knee Joint
Therapeutics
Spleen
Facial Bones
Mucopolysaccharidoses
Enzyme Replacement Therapy
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Growth Plate
Liver
Vacuoles
Radiography
Animal Models
Costs and Cost Analysis
Lung

Keywords

  • arylsulfatase B
  • glycosaminoglycan
  • liver transplantation
  • lysosomal storage disorder
  • mucopolysaccharidosis VI

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Toyama, S., Migita, O., Fujino, M., Kunieda, T., Kosuga, M., Fukuhara, Y., ... Okuyama, T. (2019). Liver transplantation: New treatment for mucopolysaccharidosis type VI in rats. Pediatrics International, 61(2), 180-189. https://doi.org/10.1111/ped.13751

Liver transplantation : New treatment for mucopolysaccharidosis type VI in rats. / Toyama, Sumika; Migita, Ohsuke; Fujino, Masayuki; Kunieda, Tetsuo; Kosuga, Motomichi; Fukuhara, Yasuyuki; Nagahara, Yukitoshi; Li, Xiao Kang; Okuyama, Torayuki.

In: Pediatrics International, Vol. 61, No. 2, 01.02.2019, p. 180-189.

Research output: Contribution to journalArticle

Toyama, S, Migita, O, Fujino, M, Kunieda, T, Kosuga, M, Fukuhara, Y, Nagahara, Y, Li, XK & Okuyama, T 2019, 'Liver transplantation: New treatment for mucopolysaccharidosis type VI in rats', Pediatrics International, vol. 61, no. 2, pp. 180-189. https://doi.org/10.1111/ped.13751
Toyama, Sumika ; Migita, Ohsuke ; Fujino, Masayuki ; Kunieda, Tetsuo ; Kosuga, Motomichi ; Fukuhara, Yasuyuki ; Nagahara, Yukitoshi ; Li, Xiao Kang ; Okuyama, Torayuki. / Liver transplantation : New treatment for mucopolysaccharidosis type VI in rats. In: Pediatrics International. 2019 ; Vol. 61, No. 2. pp. 180-189.
@article{27b89ea95bd24c8b9f7e6bf6b0e04a24,
title = "Liver transplantation: New treatment for mucopolysaccharidosis type VI in rats",
abstract = "Background: Mucopolysaccharidosis (MPS) VI is a rare, autosomal recessive congenital metabolic disorder caused by deficient activity of the lysosomal metabolic enzyme, N-acetylgalactosamine 4-sulfatase. Enzyme replacement therapy (ERT) is the current treatment for MPS VI, although it involves limited compliance to the therapy and high cost. The aim of this study was to develop a new method of treatment by conducting an orthotopic liver transplantation (LTx) using an animal model of human MPS VI, and to evaluate and examine its effectiveness for treating MPS VI. Methods: LTx was carried out from normal unaffected to affected MPS VI rats (MPR), which were then killed after LTx, and tissues from the heart, spleen, and knee joint, as well as serum, collected for biological and morphologic evaluation. Results: Liver-transplanted (LTx) MPR had the same level of N-acetylgalactosamine 4-sulfatase activity in the liver and lungs as normal unaffected MPR, and the urinary secretion of mucopolysaccharides/glycosaminoglycan (GAG) in LTx MPR was significantly decreased. Furthermore, on histopathology, the spleens of LTx MPR showed elimination of vacuole cells. In the knee joints, growth plates became thinner, and on radiography the facial and cranial bones of LTx MPR were morphologically normal. Conclusions: LTx from normal to affected MPR was effective for symptoms of MPS and accumulation of GAG, suggesting that LTx could be a promising alternative approach for MPS VI.",
keywords = "arylsulfatase B, glycosaminoglycan, liver transplantation, lysosomal storage disorder, mucopolysaccharidosis VI",
author = "Sumika Toyama and Ohsuke Migita and Masayuki Fujino and Tetsuo Kunieda and Motomichi Kosuga and Yasuyuki Fukuhara and Yukitoshi Nagahara and Li, {Xiao Kang} and Torayuki Okuyama",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/ped.13751",
language = "English",
volume = "61",
pages = "180--189",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Liver transplantation

T2 - New treatment for mucopolysaccharidosis type VI in rats

AU - Toyama, Sumika

AU - Migita, Ohsuke

AU - Fujino, Masayuki

AU - Kunieda, Tetsuo

AU - Kosuga, Motomichi

AU - Fukuhara, Yasuyuki

AU - Nagahara, Yukitoshi

AU - Li, Xiao Kang

AU - Okuyama, Torayuki

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Mucopolysaccharidosis (MPS) VI is a rare, autosomal recessive congenital metabolic disorder caused by deficient activity of the lysosomal metabolic enzyme, N-acetylgalactosamine 4-sulfatase. Enzyme replacement therapy (ERT) is the current treatment for MPS VI, although it involves limited compliance to the therapy and high cost. The aim of this study was to develop a new method of treatment by conducting an orthotopic liver transplantation (LTx) using an animal model of human MPS VI, and to evaluate and examine its effectiveness for treating MPS VI. Methods: LTx was carried out from normal unaffected to affected MPS VI rats (MPR), which were then killed after LTx, and tissues from the heart, spleen, and knee joint, as well as serum, collected for biological and morphologic evaluation. Results: Liver-transplanted (LTx) MPR had the same level of N-acetylgalactosamine 4-sulfatase activity in the liver and lungs as normal unaffected MPR, and the urinary secretion of mucopolysaccharides/glycosaminoglycan (GAG) in LTx MPR was significantly decreased. Furthermore, on histopathology, the spleens of LTx MPR showed elimination of vacuole cells. In the knee joints, growth plates became thinner, and on radiography the facial and cranial bones of LTx MPR were morphologically normal. Conclusions: LTx from normal to affected MPR was effective for symptoms of MPS and accumulation of GAG, suggesting that LTx could be a promising alternative approach for MPS VI.

AB - Background: Mucopolysaccharidosis (MPS) VI is a rare, autosomal recessive congenital metabolic disorder caused by deficient activity of the lysosomal metabolic enzyme, N-acetylgalactosamine 4-sulfatase. Enzyme replacement therapy (ERT) is the current treatment for MPS VI, although it involves limited compliance to the therapy and high cost. The aim of this study was to develop a new method of treatment by conducting an orthotopic liver transplantation (LTx) using an animal model of human MPS VI, and to evaluate and examine its effectiveness for treating MPS VI. Methods: LTx was carried out from normal unaffected to affected MPS VI rats (MPR), which were then killed after LTx, and tissues from the heart, spleen, and knee joint, as well as serum, collected for biological and morphologic evaluation. Results: Liver-transplanted (LTx) MPR had the same level of N-acetylgalactosamine 4-sulfatase activity in the liver and lungs as normal unaffected MPR, and the urinary secretion of mucopolysaccharides/glycosaminoglycan (GAG) in LTx MPR was significantly decreased. Furthermore, on histopathology, the spleens of LTx MPR showed elimination of vacuole cells. In the knee joints, growth plates became thinner, and on radiography the facial and cranial bones of LTx MPR were morphologically normal. Conclusions: LTx from normal to affected MPR was effective for symptoms of MPS and accumulation of GAG, suggesting that LTx could be a promising alternative approach for MPS VI.

KW - arylsulfatase B

KW - glycosaminoglycan

KW - liver transplantation

KW - lysosomal storage disorder

KW - mucopolysaccharidosis VI

UR - http://www.scopus.com/inward/record.url?scp=85062061861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062061861&partnerID=8YFLogxK

U2 - 10.1111/ped.13751

DO - 10.1111/ped.13751

M3 - Article

C2 - 30548979

AN - SCOPUS:85062061861

VL - 61

SP - 180

EP - 189

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 2

ER -